Marinova set to triple manufacturing capacity | Latest news

Marinova set to triple manufacturing capacity

Marinova is pleased to announce the commencement of a $5 million expansion to its state-of-the-art advanced manufacturing facility in Tasmania, Australia.

Marinova is a specialist producer of fucoidan – a bioactive compound found naturally in brown seaweeds. Fucoidan is highly prized for its range of beneficial health properties, particularly in the areas of immune support, gut and digestive health, and healthy ageing.

“Marinova is the world’s only producer of high purity, certified organic fucoidan with global regulatory acceptance,” explained company CEO & Managing Director, Mr Paul Garrott. “Global demand for Maritech® organic fucoidan has increased markedly in recent years. The company now exports its novel seaweed extracts to over 35 countries across the globe and is the supplier of choice to the world’s most respected nutritional, pharmaceutical and skincare companies.”

“Maritech® fucoidan ingredients are increasingly being utilised in medical devices, nutritional supplements, animal health and dermatological products,” continued Mr Garrott. “Their success is driven by Marinova’s ongoing investment in innovative R&D, the company’s unique green chemistry extraction process, and a genuine commitment to sustainability. Maritech® is a brand that has become synonymous with quality.”

The expansion of Marinova’s fucoidan extraction facility is being supported by the Australian Government’s Modern Manufacturing Initiative. The initiative provides businesses with funding to support projects that translate high quality research into commercial outcomes and supports businesses to adopt new technologies and improve their manufacturing processes. The project also received support through the Tasmanian Government’s Building Projects Support Program and Advanced Manufacturing Accelerating Growth Program.

“This expansion will allow Marinova to triple its fucoidan production capacity,” said Mr Garrott. “It will involve significant investment in advanced manufacturing technologies and will create highly skilled new jobs at our facility in Tasmania. This extensive capital investment will enable Marinova to readily meet the rising demand for its high purity extracts, particularly from the global medical and consumer healthcare sectors.”

News index

Fucoidan progresses diabetes research | Latest news

Fucoidan progresses diabetes research

Diabetes mellitus is a chronic metabolic disease. Characterised by abnormally high blood sugar levels, it can lead to serious damage of the heart, eyes, kidneys, blood vessels and nerves. The World Health Organization has reported that diabetes is a major cause of conditions including blindness, kidney failure, heart attack and stroke. As the seventh most common cause of death globally, the development of new therapies to treat diabetes is critical.

A new in vitro study utilised high purity fucoidan to develop versatile carriers for potential use in diabetes therapies, including the delivery of insulin. Hydrogel particles that encapsulate insulin may serve to protect the drug against acidity and enzymatic attack in the stomach and to release it where it is required – at the cellular membrane. The study successfully established a methodology for the production of fucoidan hydrogel particles loaded with insulin and the particles were shown to release the insulin in a sustained fashion.

The fucoidan hydrogel particles also supported the culture and encapsulation of human pancreatic beta cells that makes insulin. Researchers suggested that the fucoidan hydrogel particles are a good candidate for a drug delivery vehicle or immune-protectant devices for insulin-producing pancreatic cells.

High purity Fucus vesiculosus fucoidan, manufactured in Australia by Marinova was utilised in the study.

The full paper, ‘Fucoidan-based hydrogels particles as versatile carriers for diabetes treatment strategies’, was published in the Journal of Biomaterials Science.

News index

Seaweed farming and sustainable development | Latest news

Seaweed farming and sustainable development

There is widespread interest in the farming of seaweeds to address a range of global issues, including food security, climate change and ecosystem management.

A new Australian paper has delivered the first comprehensive overview of the possible opportunities and threats presented by large-scale seaweed farming. Drawing together the perspectives of expert stakeholders from across the seaweed industry, the paper discussed the potential impacts of seaweed farming on sustainability, with particular focus on the Sustainable Development Goals (SDGs) developed by the United Nations.

The in-depth study of opinions collected across a series of stakeholder workshops, concluded that seaweed farming is likely to contribute diverse benefits to a number of the SDGs, most notably SDG 2 (Zero Hunger), SDG 8 (Decent Work and Economic Growth) SDG 9 (Industry, Innovation and Infrastructure), SDG 12 (Sustainable Production and Consumption) and SDG 15 (Life on Land). It also noted that without appropriate measures in place to mitigate potential impacts, seaweed farming may not succeed in supporting some goals, chiefly SDG 14 (Life Below Water).

Researchers highlighted a range of contemporary issues that will require resolution for the success of large-scale seaweed farming. These included the development of effective management plans, farm designs, spatial allocation and regulatory frameworks. They also noted the importance of a genuine transdisciplinary approach in achieving broader success – including liaison with industry, investors, indigenous communities, stakeholders, researchers and regulators.

The full paper, “Expert perceptions of seaweed farming for sustainable development” was published in the Journal of Cleaner Production.

News index

Maritech® organic fucoidans scoop global award | Latest news

Maritech® organic fucoidans scoop global award

Maritech® organic fucoidans have been crowned Most Innovative Ingredient 2022 (Australasia) in the annual Global Health & Pharma International Life Sciences Awards.

Fucoidans are highly bioactive compounds that occur naturally in brown seaweeds. They have been extensively researched and are particularly well known for their bioactivity across a range of health settings including immune support, gut and digestive health and healthy ageing.

Manufactured by Marinova Pty Ltd, Maritech® organic fucoidans are the world’s only high purity, certified organic fucoidans with global regulatory acceptance.

Speaking of the award, company CEO Mr Paul Garrott said, “The unrivalled quality and efficacy of Maritech® fucoidans is based on two decades of rigorous scientific investigation and the development of an advanced proprietary extraction process. Maritech® organic fucoidans are ideal for product innovators seeking novel ingredients with a clear point of differentiation.”

Sustainably sourced and clinically validated, Maritech® organic fucoidans are high purity seaweed extracts sought after by some of the world’s most trusted healthcare brands. They are utilised in pharmaceutical research and medical devices and are also included as premium ingredients in market-leading nutritional supplements, functional foods and beverages, skincare and dermatological formulations, and animal health products.

Operated by Global Health & Pharma magazine, and now in their seventh year, the International Life Sciences Awards recognise innovation throughout the life sciences industry.

The official awards supplement is now available on the Global Health & Pharma website.

Marinova’s unique Maritech® organic fucoidan portfolio is profiled on the Maritech® fucoidan website.

News index

Research indicates fucoidan promotes antiviral activity | Latest news

Research indicates fucoidan promotes antiviral activity

Over the past two decades, extensive research has explored the ability of high purity fucoidan extracts to inhibit viral activity.

Recent in vitro research further builds on this existing evidence, investigating some of the possible mechanisms behind the antiviral activity. A Korean study examined changes in bone marrow-derived dendritic cells using RNA sequencing. The study found that cells treated with fucoidan activated the key genes involved in virus-specific response pathways, including those of coronaviruses and influenza. The fucoidan-treated cells also increased type 1 interferon response which plays an essential role in combating virus infection.

The researchers concluded that the findings may serve as a strong foundation for further research into fucoidan-based strategies for the prevention and treatment of a range of viruses.  

The study included high purity Fucus vesiculosus fucoidan produced by Marinova Pty Ltd in Australia.

The full paper, ‘Gene Set Enrichment Analysis Reveals That Fucoidan Induces Type I IFN Pathways in BMDC’ was published in the journal Nutrients.

News index

Fucoidan promising for gastroenteritis relief | Latest news

Fucoidan promising for gastroenteritis relief

A new study has shown that the marine polysaccharide fucoidan may inhibit norovirus replication by enhancing innate immune response.

Norovirus infections are a leading cause of epidemic and sporadic gastroenteritis worldwide. Gastroenteritis caused by norovirus usually starts suddenly and causes vomiting and watery diarrhoea. Sufferers may also experience nausea, fever, stomach pains, headache, muscle aches and dehydration. Symptoms usually begin between 24 and 48 hours after exposure to the virus and generally last for one or two days. It is highly contagious and quickly spreads in day care centres, schools and other institutional settings. There are currently no preventative vaccines or antiviral treatments for norovirus.

Previous in vitro research has shown that fucoidans, a group of natural compounds derived from brown seaweed, may be an inhibitor of noroviral entry to cells. A number of pre-clinical studies indicate the potential for fucoidan to both lessen the symptoms of norovirus and reduce the spread of infection.

A new study utilising zebrafish larvae has shown that a high purity fucoidan extract enhanced the innate immune response of the host. The fucoidan inhibited the replication of human norovirus and also significantly upregulated genes associated with interferon signalling.

Speaking of the study, Marinova Research Scientist and co-author of the paper, Dr Ahyoung Park said, “These results suggest exciting potential for high purity fucoidan to address the symptoms of norovirus. We can expect to see increasing interest in the use of fucoidan for this application.”

The high purity fucoidan utilised in the study was extracted from Fucus vesiculosus seaweed by Marinova Pty Ltd.

The paper, ‘Fucoidan from Fucus vesiculosus can inhibit human norovirus replication by enhancing the host innate immune response’ was published in the Journal of Functional Foods.

News index

Fucoidan-polydopamine composite shows potential for periodontal health | Latest news

Fucoidan-polydopamine composite shows potential for periodontal health

In recent years, fucoidan has been identified as being a natural biomaterial with potential to support bone formation and regeneration. For fucoidan composites to be utilised in future bone engineering applications, a deeper understanding of the osteogenic processes involved at molecular level is required.

A recent in vitro study designed a fucoidan and polydopamine composite-based film for use in a culture with periodontal ligament stem cells. The study then investigated the effects of the composite on a number of osteogenic molecular pathways. The research concluded that a fucoidan-polydopamine composite has the potential to promote bone regeneration by activating prominent molecular pathways.

The fucoidan involved in the study was a high purity extract derived from the seaweed Undaria pinnatifida, produced in Australia by Marinova. 

The full paper, ‘Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface Promotes Osteogenic Potential of Periodontal Ligament Stem Cells’ was published in Marine Drugs.

News index

Regenerative medicine: Hydrogel a promising delivery system for fucoidan | Latest news

Regenerative medicine: Hydrogel a promising delivery system for fucoidan

Fucoidans are promising candidates for use in regenerative medicine. They have been shown to exhibit a range of bioactive properties essential for bone and tissue regeneration. In order to progress research in this field, an effective delivery system is required to release fucoidan directly at the wound site.

A new paper describes the successful development of a hydrogel delivery system for fucoidan. Researchers developed an injectable thermosensitive hydrogel that released high purity fucoidan over the course of six days. In comparison to solid materials, injectable hydrogels offer a number of advantages. These include application via minimally invasive injection and the ability to readily adapt to the exact shape of the wound.

The study showed that the physicochemical properties of the hydrogel were not affected by the integration of fucoidan. It was also biocompatible with human bone-derived mesenchymal stem cells and human outgrowth endothelial cells. Researchers concluded that the injectable hydrogel represents a promising delivery system for fucoidan for application in regenerative medicine.

The high purity Fucus vesiculosus fucoidan utilised in the study was produced in Australia by Marinova Pty Ltd.

The full paper, ‘Injectable Thermosensitive Chitosan-Collagen Hydrogel as A Delivery System for Marine Polysaccharide Fucoidan’ was published in Marine Drugs.

News index

International Seaweed Symposium to be held in Australia | Latest news

International Seaweed Symposium to be held in Australia

The 24th International Seaweed Symposium (ISS) will be held in Australia during February 2023. The event is scheduled to take place in Tasmania, Australia’s southernmost state, from February 19 – 24, 2023.

The 24th ISS committee has selected the theme ‘Seaweeds in a changing world’, to focus on ongoing changes in seaweed aquaculture practices, industrial processing, future products and markets, local and global environmental change, and the scientific advances that are predicted to progress our understanding of how seaweeds function.

Planning for the symposium is well advanced and a vibrant hybrid conference style is anticipated. In light of the COVID-19 pandemic, the symposium format will embrace new technologies allowing both actual and virtual delegates to attend and interact.

Marinova is pleased to be a sponsor of the event. Speaking of the ISS, the company’s Marketing & Communications Manager, Mrs Amanda Mackinnon, said, “The seaweed industry is gaining momentum across the globe. Marinova is pleased to support the ISS which will undoubtedly bring together global experts in the field to share their knowledge and experience. With the event being held right on our doorstep in the city of Hobart, Marinova is looking forward to welcoming delegates for a unique Tasmanian experience.”

Further details about the ISS are available here.

News index

Meet the Marinova team at SupplySide West | Latest news

Meet the Marinova team at SupplySide West

Marinova extends a warm invitation to meet its team of fucoidan experts at SupplySide West in Las Vegas in November 2022.

As the global leader in fucoidan science, Marinova is looking forward to sharing the latest research and presenting its range of market leading fucoidan extracts. With a surge of interest in marine ingredients currently sweeping the globe, Marinova staff will be on hand to discuss the comprehensive clinical evidence supporting the world’s only high purity, certified organic fucoidan extracts with global regulatory acceptance.

The recent lifting of international travel restrictions for Australians has been welcomed by Marinova. The company’s team is looking forward to reconnecting with valued partners in person, and establishing new global connections with brands that share a passion for high quality ingredients.  

Marinova staff will be in Las Vegas from Tuesday November 1 – Friday November 4, including at SupplySide West booth #2719 on Wednesday November 2 and Thursday November 3.

To schedule an appointment, please contact the team today. 

News index